Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

QuidelOrtho launches certified analyzer program

October 2025—QuidelOrtho Corp. has launched a certified analyzer program designed to expand access to high-quality diagnostic testing in rural and community hospitals across the United States. The program is tailored for clinics, physician office labs, and small hospitals with fewer than 100 beds. Each analyzer in the program undergoes a robust, multipoint certification process at QuidelOrtho’s Rochester, NY, facility. It includes more than 140 system checks, functional adjustments, hardware cleaning or replacement, and extensive performance testing. The program features certified Vitros XT 7600 and 5600 integrated systems and the Vitros 3600 immunodiagnostic system. A 12-month warranty on service and support is included.

StatLab launches PiSmart S1 slide printer

October 2025—StatLab Medical Products has launched the PiSmart S1 single hopper slide printer. The PiSmart S1 features an intuitive touchscreen interface and a compact footprint that supports on-demand printing. Four years of service is included with the use of StatLab-validated slides, which will soon be manufactured at the company’s Arlington, Tex., facility. This integrated approach—pairing printers with precision-manufactured, validated KT premium slides—creates a complete solution built for accuracy and reliability, according to a press release from StatLab.

Idylla CDx MSI test gets FDA premarket approval

October 2025—Biocartis’ Idylla CDx MSI test, developed in partnership with Bristol Myers Squibb, has received FDA premarket approval. The test aids in identifying eligible microsatellite instability-high colorectal cancer patients who may benefit from treatment with Opdivo (nivolumab) alone or in combination with Yervoy (ipilimumab), as established in the CheckMate 8HW trial.

Bio-Rad launches Unity Next Peer QC in Asia-Pacific region

October 2025—Bio-Rad Laboratories has launched its Unity Next Peer QC data management software throughout the Asia-Pacific region. The software is designed to help troubleshoot quality control errors and increase confidence in patient testing results. It offers on-demand access to peer reporting and quality control data and provides data visualization and report generation for compliance management. Labs new to Bio-Rad’s suite of QC data management products can get guided support and training from the company.

Randox expands its operations in West Virginia

October 2025—Randox Laboratories plans to expand its facility in Jefferson County, W. Va., from a 48-person sales and distribution operation to a full-scale production laboratory. The company says the expansion will further increase its annual production of 4.1 billion tests and significantly enhance its capacity to serve customers worldwide, from hospitals, laboratories, and coroners’ offices to food safety testing facilities. The project will create opportunities for local suppliers and service providers. Once complete, the upgraded facility in Kearneysville will produce next-generation diagnostic products and equipment.

Scopio receives fourth FDA clearance

October 2025—Scopio Labs received FDA clearance to include decision support system features for its X100 and X100HT platforms and Peripheral Blood Smear Application. The upgraded solution provides AI-driven analysis and grading for 23 distinct RBC morphology parameters and for the presence of platelet clumps across the clinically relevant areas of the sample, from the monolayer to the feathered edge.

New book on interpreting coagulation test results

October 2025—Knowledge of laboratory tests that most effectively work up a patient presenting with bleeding or clotting manifestations is crucial to develop a sound and timely action plan for the benefit of the patient. It is important for medical professionals to know which tests best evaluate the causes of hemostasis disorders and what common clinical scenarios can significantly interfere with accurate test results, such as the impact of anticoagulant agents on routine and special coagulation assay results.

Roche mass spec test categorized as moderate complexity

October 2025—The Food and Drug Administration has categorized Roche’s Ionify 25-Hydroxy Vitamin D total assay as moderate complexity under the Clinical Laboratory Improvement Amendments of 1988. Roche reported that this is the first time a mass-spectrometry-based test has achieved this designation.

Eppendorf introduces next-generation mechanical pipettes

October 2025—Eppendorf has launched the Eppendorf Research 3 Neo mechanical pipette. Users can choose between two volume settings and speeds. The pipette can be adjusted for different liquid types, tip geometries, and reverse pipetting and a volume lock feature prevents unintentional volume changes. The use of ColorTag marking rings provides color-coded identification.

Haystack MRD ctDNA test gets breakthrough device designation

October 2025—The Food and Drug Administration has granted breakthrough device designation for Quest Diagnostic’s Haystack MRD circulating tumor DNA test. The test is used for identifying minimal residual disease in patients with stage two colorectal cancer following curative-intent surgical treatment who may benefit from adjuvant therapy in accordance with therapeutic product labeling.

MARKETPLACE

TRENDING